Should we treat children with idiopathic short stature? Workshop held in St.-Paul-de-Vence, France, April 18-19, 1999

C. J.H. Kelnar, K. Albertsson-Wikland, R. L. Hintz, M. B. Ranke, R. G. Rosenfeld

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

The use of growth hormone (GH) to treat short children who are clearly GH-deficient is now well accepted. However, GH treatment of short children who have no currently recognizable abnormalities in their GH-insulin-like growth factor I axis remains controversial. Whether such children with so-called idiopathic short stature (ISS) should be treated with GH was the subject of an international workshop held in St.-Paul-de-Vence, France, in April 1999. This article summarizes the issues discussed at the workshop, including the definition of ISS, ethical and health-economic aspects of treatment, results from clinical trials and surveillance studies, and the use of prediction models in aiding treatment decisions. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish (US)
Pages (from-to)150-157
Number of pages8
JournalHormone Research
Volume52
Issue number3
StatePublished - Dec 1 1999

Keywords

  • Growth
  • Growth hormone
  • Height, final
  • Prediction model, height
  • Quality of life
  • Short stature, idiopathic

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Should we treat children with idiopathic short stature? Workshop held in St.-Paul-de-Vence, France, April 18-19, 1999'. Together they form a unique fingerprint.

  • Cite this

    Kelnar, C. J. H., Albertsson-Wikland, K., Hintz, R. L., Ranke, M. B., & Rosenfeld, R. G. (1999). Should we treat children with idiopathic short stature? Workshop held in St.-Paul-de-Vence, France, April 18-19, 1999. Hormone Research, 52(3), 150-157.